What Is the RDI-Lancet Commission for Rare Disease and What Will It Achieve?
December 23, 2025 |
Christy Rohani-Montez, Medscape’s Rare Disease Education Lead recently spoke with Dr Lucy McKay, CEO, and Megan Pullein, Strategic Operations Officer from the UK-based charity Medics for Rare Disease (MfRD). We discussed their involvement in the recently formed RDI-Lancet Commission for Rare Diseases, a global initiative aimed at developing evidence-based recommendations to improve the lives of the 400 million people living with rare diseases worldwide.
Lucy McKay Megan Pullein
CEO Strategic Operations Officer
Medics for Rare Disease Medics for Rare Disease
Christy: It’s lovely to be speaking with one of our favourite partners in rare disease, Medics for Rare Disease! Lucy, and Megan, could you start by introducing yourselves, Medics for Rare Disease, and its mission?
Lucy: Absolutely, I’m Dr Lucy McKay, the CEO of Medics for Rare Disease, and our vision is simple: equitable healthcare for everyone. Our mission is to shape a medical profession that can provide timely diagnosis and excellent care to people living with rare diseases.
Megan: I’m Megan Pullein, and I’m the Strategic Operations Officer at Medics for Rare Disease. My primary role is to help manage our work with the RDI-Lancet Commission, specifically for Working Group 2, which Lucy Co-Chairs.
Christy: What are the Lancet Commissions, and what is the RDI-Lancet Commission for Rare Diseases?
Megan: The Lancet Commissions are in-depth research initiatives that tackle urgent and complex global health issues. They gather experts from around the world to collaborate on solutions, which are then published in the renowned medical journal. The vision for this specific commission is to make rare diseases visible globally, ensuring that every person is seen, heard, and cared for, no matter where they live. The goal is to produce actionable recommendations that any government can take and implement within their society.
Christy: I understand that the commission is divided into 5 working groups. What is the focus of each?
Lucy: Before breaking down the groups, it’s important to state the golden thread that runs through all of this: human rights. The entire commission is fundamentally about achieving equity for patients around the world.
Megan: That leads perfectly into Working Group 1, which is focused on visibility for human rights. This is the core of the commission. Working Group 2, which we are leading, focuses on visibility for social justice. These are the 2 overarching themes. The other groups are more specific: Group 3 is looking at data and metrics; Group 4 is tackling visibility within healthcare systems, particularly the diagnostic odyssey; and Group 5 is focused on clinical pathways and trials.
Christy: Where does the work for each group start, and where does it end?
Lucy: We’re working in 3 phases. For example, in Working Group 2, first is a comprehensive literature review to answer the question: is social justice being achieved for people living with rare disease? If so, how? And if not, why not?
The second phase is generating new evidence. We want to fill the gaps we find in the literature, especially from geographical and demographical sources that are currently missing. We have a lofty goal of trying to represent advocates from every UN-recognized country, starting with the places from which we hear no voices.
The final phase will be to consolidate this evidence into concrete recommendations.
Christy: What do you find most exciting about RDI-Lancet Commission?
Lucy: For The Lancet to even highlight Rare Disease is a major milestone in history. What excites me is that this project forces us to pull back to focus on the individual. We constantly have to ask, for example, How is this recommendation going to help someone in rural Chile? It moves the conversation beyond tech, molecules, and industry chatter. Tech doesn’t matter to people if they can’t access it or are being treated without the respect every human being deserves.
It allows us to establish a global standard of provision for the rare disease community and will help shape The World Health Organisation’s Global Action Plan for Rare Disease. We hope that in the future there will be greater standardisation and transparency in how nations care for rare diseases. This will empower the rare disease community to understand what they are entitled to, the barriers to access and to demand accountability.
Christy: Thank you so much Lucy and Megan, it’s exciting to see this research moving forward, and we’re all looking forward to seeing the forthcoming publications.
For more information on the RDI-Lancet Commission:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00211-9/abstract
About Medscape Education
Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses for physicians, nurses, and other healthcare professional
This content was provided by Medscape Education
Company Details
Latest Content from Medscape Education
Medscape Education Demonstrates Deep Cardiology Outcomes Expertise at ACC 2023
As cardiologists from around the world return home from New Orleans and ACC 2023, Medscape Education is looking back at a successful conference.At this year’s event, the Medscape Education team...
Rare Diseases on Medscape Education: Pustular Psoriasis
Rare Disease Day may be over but our committment to advancing outcomes for patients continues. Watch this video to understand a patient's journey with pustular psoriasis.To learn more about Medscape's rare...
Rare Diseases on Medscape Education: Long-Chain Fatty Acid Oxidation Disorder
Rare Disease Day may be over but our committment to advancing outcomes for patients continues. Listen to a mother explain her daughter's journey with a long-chain fatty acid oxidation disorder.To...
Medscape Expands Global Reach with Acquisition of Health Information Platform Grupo SANED
WebMD Health Corp., an Internet Brands company and a leader in health information services for physicians, other healthcare professionals and consumers, today announced that it has acquired Grupo SANED, Spain's leader in...
Medscape Oncology: Delivering Impact at ASH
You can read more information on Medscape Oncology at ASH here, or please reach out to Chris Carey or Steve Dunn who can tell you more about how Medscape can help to...
Medscape Oncology: Delivering Impact at ASH
Medscape Oncology was on-site in New Orleans at ASH 2022. During the 4-day conference, Medscape Oncology hosted educational symposia, interacted with clinicians at our booth, and worked with leading faculty...
Medscape Education: Rare Diseases PAH
Today is Rare Disease Day, February 28.Hear from Helen as she describes in her own words what it’s like to live with PAH, and her perspective as a patient. To learn...
Medscape Education and M4RD: Together Caring for Rare Disease
We are excited to finally share our news-style video ' ', developed in partnership with Medics 4 Rare Diseases (M4RD) and produced by Genetic Alliance UK and ITN Business.For more information on...
The Need for and Impact of Rare Disease Education
Physicians are often told that when they hear hoofbeats, think horses, not zebras — to look for the most common cause of a patient’s symptoms first. While this advice may...
Medscape Education: Rare Diseases Fibrodysplasia Ossificans Progressiva
Rare Disease Day is on February 28.Listen to Nicky explain her daughter's journey with fibrodysplasia ossificans progressiva.Many patients face long waits for accurate diagnosis and treatment, making it critically important...